

# Clinical Summary

Consistent Outcomes Across 4 RCTs in Patients without Collateral Ventilation

**zephyr**<sup>®</sup>  
valve

RCT	Design	Sample Size & Follow-up Period	Procedural Success (TLVR%)	Difference Zephyr <sup>®</sup> Valve vs Control Group (ITT analysis)		
				LUNG FUNCTION (FEV <sub>1</sub> %) MCID=10%–15%	EXERCISE CAPACITY (6MWD) MCID=26 m	QUALITY OF LIFE (SGRQ) MCID=-4 pts
<b>LIBERATE</b> <sup>1</sup>	2:1 Randomization <b>Heterogenous only</b> Multicenter	n=190 12 months	<b>84%</b>	<b>18.0%</b> p<0.001	<b>39 m</b> p=0.002	<b>-7.1 pts</b> p=0.004
<b>TRANSFORM</b> <sup>2</sup>	2:1 Randomization <b>Heterogenous only</b> Multicenter	n=97 6 months	<b>90%</b>	<b>29.3%</b> p<0.001	<b>79 m</b> p<0.001	<b>-6.5 pts</b> p=0.031
<b>IMPACT</b> <sup>3</sup>	1:1 Randomization <b>Homogenous only</b> Multicenter	n=93 6 months*	<b>89%</b>	<b>16.3%</b> p<0.001	<b>28 m</b> p=0.016	<b>-7.5 pts</b> p<0.001
<b>STELVIO</b> <sup>4</sup>	1:1 Randomization <b>Heterogenous &amp; Homogenous</b> Single Center	n=68 6 months	<b>88%</b>	<b>17.8%</b> p=0.001	<b>74 m</b> p<0.001	<b>-14.7 pts**</b> p<0.001

\*Data on file at PMX (not in publication)

\*\*Completed cases, all other values listed are ITT population

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Endobronchial Valves, such as Zephyr Valves, are included in global and national guidelines for the treatment of severe emphysema, such as those sponsored by:



**>20,000**  
patients treated globally



- Global Initiative for Chronic Obstructive Lung Disease (GOLD)
- The Australian Lung Foundation — COPD-X Concise Guide for Primary Care
- German Respiratory Society (DGP)
- The UK's National Institute for Health and Care Excellence (NICE)
- National Health Care Institute of the Netherlands (Zorginstituut Nederland)

Contact us for more information: [info@pulmonx.com.au](mailto:info@pulmonx.com.au)

1. Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151–1164
2. Kemp, SV et al. Am J Respir Crit Care Med. 2017 Dec 15;196(12):1535–1543
3. Valipour, A et al. Am J Respir Crit Care Med. 2016 Nov 1;194(9):1073–1082 and data on file at Pulmonx
4. Klooster, K et al. N Engl J Med. 2015 Dec 10;373(24):2325–2335

**International Brief Statement:** The Zephyr® Endobronchial Valve is an implantable bronchial valve intended to control airflow in order to improve lung functions in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; Evidence of active pulmonary infection; Patients with known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); Patients with known allergies to silicone; Patients who have not quit smoking. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.



**Pulmonx Australia Pty Limited**  
ABN 91 160 455 925, Suite 5, Level 6  
65 York Street Sydney, NSW 2000 Australia  
P: 1300 785 666 | E: [Info@pulmonx.com.au](mailto:Info@pulmonx.com.au)  
Visit our website: [pulmonx.com.au](http://pulmonx.com.au)

© 2021 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners.  
GLO-EN-175-v2 May 2021 Clinical Summary